A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib
The primary purpose of this study is to evaluate the efficacy of the study drug known as
LY2875358, administered alone or in combination with a second drug named Erlotinib, in
participants affected by a defined type of lung cancer (MET biomarker diagnostic positive
Non-Small-Cell Lung Cancer) that experienced a disease progression during the most recent
treatment with Erlotinib.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.